All In Biotech

NDA 021632 · Vicuron Holdings

Eraxis

Anidulafungin · Intravenous · Echinocandin Antifungal

Novel

Last checked: Nov 20, 2026Latest source record: Oct 5, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Feb 17, 2006

Approved uses

2

Original approval plus efficacy supplements

Registered trials

34

15 Phase 3, 0 recruiting

FAERS reports

1,627

1,582 serious, 692 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 19, 2025.

ERAXIS is an echinocandin antifungal indicated for the treatment of the following infections: • Candidemia and other forms of Candida infections (intra-abdominal abscess and peritonitis) in adults and pediatric patients (1 month of age and older) ( 1.1 ) • Esophageal candidiasis in adults ( 1.2 ) Limitations of use • ERAXIS has not been studied in adult and pediatric patients with endocarditis, osteomyelitis, and meningitis due to Candida or in sufficient numbers of neutropenic patients. The dosage of ERAXIS for the treatment of Candida dissemination into the CNS and the eye has not been established. ( 1.3 , 5.3 , 8.4 ) • ERAXIS is associated with high relapse rates in esophageal candidiasis. ( 1.3 , 14.2 ) 1.1 Candidemia and Other Forms of Candida Infections (Intra-abdominal Abscess and Peritonitis) ERAXIS is indicated for the treatment of candidemia and the following Candida infections: intra-abdominal abscess and peritonitis in adults and pediatric patients 1 month of age and older [see Clinical Studies (14.1) and Microbiology (12.4) ] . 1.2 Esophageal Candidiasis ERAXIS is indicated for the treatment of esophageal candidiasis in adults [see Indications and Usage (1.3) , Clinical Studies (14.2) ] . 1.3 Limitations of Use • ERAXIS has not been studied in adult and pediatric patients with endocarditis, osteomyelitis, and meningitis due to Candida , and has not been studied in sufficient numbers of neutropenic patients to determine efficacy in this group. The dosage of ERAXIS for the treatment of Candida dissemination into the CNS and the eye has not been established [see Warning and Precautions (5.3) , Use in Specific Populations (8.4) ] . • ERAXIS is associated with high relapse rates in esophageal candidiasis [see Clinical Studies (14.2) ] . 1.4 Usage Specimens for...

Mechanism: Anidulafungin is an anti-fungal drug [see Microbiology (12.4) ].

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • ERAXIS · ANIDULAFUNGIN 50MG/VIAL · POWDER, INTRAVENOUS · Prescription
  • ERAXIS · ANIDULAFUNGIN 100MG/VIAL · POWDER, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Anidulafungin" as an intervention, any sponsor and status, largest first.

All 34 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective393
  • off label use187
  • multiple organ dysfunction syndrome174
  • septic shock128
  • sepsis118
  • pneumonia94
  • candida infection92
  • pyrexia92
  • neutropenia85
  • death80
  • drug resistance72
  • condition aggravated70

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20068
200718
200812
200924
201036
201147
201228
201324
201422
201521
201652
201770
2018118
2019122
2020123
2021138
2022189
2023174
2024157
2025145
202699

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Eraxis (Anidulafungin)

2024 spending

$483K

Beneficiaries

134

529 claims

Per beneficiary

$3,602

$92.83 per unit

View as table
YearSpending
2020$590,076
2021$759,886
2022$475,972
2023$593,317
2024$482,685

Part B: Eraxis* (Anidulafungin*) · HCPCS J0348

2024 spending

$7K

Beneficiaries

11

128 claims

Per beneficiary

$599

2024 ASP limit $0.48 per unit

View as table
YearSpending
2020$6,231
2021$9,647
2022$17,869
2023$7,547
2024$6,594

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 57 on PubMed

Sponsor: Vicuron Holdings

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.